Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06923527 · ClinicalTrials.gov registry record · Phase 2
Circulating Tumor DNA
A Phase 2 study of ER+ Breast Cancer, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT06923527 is a Phase 2 study of ER+ Breast Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants, below the 83-participant average among 8 other ER+ Breast Cancer trials with a reported enrollment target (40% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT06923527, a Phase 2 study of ER+ Breast Cancer, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
Conditions Studied
Interventions
- DRUG Elacestrant
Study Locations (7)
Connecticut
- Yale University - New Haven
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
Maryland
- Sidney Kimmel Comprehensive Cancer Center at John Hopkins - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Montefiore Einstein Comprehensive Cancer Center - The Bronx
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06923527
The ClinicalTrials.gov registry entry for NCT06923527 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 8 other ER+ Breast Cancer trials with a reported enrollment target (40% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ER+ Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Elacestrant is the first listed.
NCT06923527 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Connecticut, District of Columbia, Maryland.
Frequently Asked Questions
What is clinical trial NCT06923527 about?
NCT06923527 is a clinical study titled "Circulating Tumor DNA". This is a single-arm, phase II study examining elacestrant in the adjuvant treatment of patients with ER+ breast cancer who test positive for circulating tumor DNA (ctDNA) during the screening period of the trial. Our trial will proceed in three separate phases: screening, treatment, and follow-up.
What is the current status of trial NCT06923527?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-09-30. Estimated completion is 2027-09.
What conditions does trial NCT06923527 study?
This clinical trial studies the following conditions: ER+ Breast Cancer.
What interventions are being tested in trial NCT06923527?
The interventions under investigation include: Elacestrant (DRUG).
Who is sponsoring clinical trial NCT06923527?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06923527 being conducted?
This trial has 7 study locations across Connecticut, District of Columbia, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ER+ Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
RECRUITING · Phase 2
-
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
RECRUITING · Phase 2
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Breast Re-irradiation After Second Ipsilateral Lumpectomy
RECRUITING · NA
-
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.